JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Danaher Corp

Geschlossen

BrancheGesundheitswesen

223.58 0.49

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

223.09

Max

223.98

Schlüsselkennzahlen

By Trading Economics

Einkommen

-399M

555M

Verkäufe

195M

5.9B

KGV

Branchendurchschnitt

44.433

37.461

EPS

0.77

Dividendenrendite

0.56

Gewinnspanne

9.35

Angestellte

61,000

EBITDA

-455M

1.3B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+9.17% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.56%

2.33%

Nächste Dividendenausschüttung

31. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

15B

150B

Vorheriger Eröffnungskurs

223.09

Vorheriger Schlusskurs

223.58

Nachrichtenstimmung

By Acuity

39%

61%

111 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Danaher Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Okt. 2025, 17:41 UTC

Ergebnisse

Danaher 3Q Earnings Rise; Pharma R&D Spend Expected to Rebound -- Update

21. Okt. 2025, 10:28 UTC

Ergebnisse

Danaher 3Q Sales and Profit Rise on Bioprocessing Momentum

22. Juli 2025, 11:32 UTC

Ergebnisse

Danaher Posts Lower 2Q Profit, Names Next CFO -- Update

22. Juli 2025, 10:42 UTC

Ergebnisse

Danaher Posts Higher 2Q Sales, Lower Profit

22. Apr. 2025, 10:34 UTC

Ergebnisse

Danaher 1Q Results Decline But Top Estimates

21. Okt. 2025, 10:02 UTC

Ergebnisse

Danaher 3Q Adjusted Core Revenue Rose 3% >DHR

21. Okt. 2025, 10:01 UTC

Ergebnisse

Danaher Sees 2025 Adjusted Core Revenue Up Low-Single Digits >DHR

21. Okt. 2025, 10:01 UTC

Ergebnisse

Danaher Backs 2025 View of Adj EPS $7.70-Adj EPS $7.80 >DHR

21. Okt. 2025, 10:00 UTC

Ergebnisse

Danaher 3Q Operating Cash Flow $1.7B, Free Cash Flow $1.4B >DHR

21. Okt. 2025, 10:00 UTC

Ergebnisse

Danaher 3Q Net $908M >DHR

21. Okt. 2025, 10:00 UTC

Ergebnisse

Danaher 3Q Sales $6.05B >DHR

21. Okt. 2025, 10:00 UTC

Ergebnisse

Danaher 3Q Adj EPS $1.89 >DHR

21. Okt. 2025, 10:00 UTC

Ergebnisse

Danaher 3Q EPS $1.27 >DHR

22. Juli 2025, 10:03 UTC

Ergebnisse

Danaher Had Seen 2025 Adjusted EPS $7.60-$7.75 >DHR

22. Juli 2025, 10:03 UTC

Ergebnisse

Danaher Raises 2025 View To Adj EPS $7.70-Adj EPS $7.80 >DHR

22. Juli 2025, 10:02 UTC

Ergebnisse

Danaher Still Sees 2025 Core Revenue Up About 3% >DHR

22. Juli 2025, 10:01 UTC

Ergebnisse

Danaher Sees 3Q Core Revenue Up Low-Single Digits >DHR

22. Juli 2025, 10:00 UTC

Ergebnisse

Danaher 2Q Operating Cash Flow $1.3B, Free Cash Flow $1.1B >DHR

22. Juli 2025, 10:00 UTC

Ergebnisse

Danaher 2Q Net $555M >DHR

22. Juli 2025, 10:00 UTC

Ergebnisse

Danaher 2Q Sales $5.9B >DHR

22. Juli 2025, 10:00 UTC

Ergebnisse

Danaher 2Q Adj EPS $1.80 >DHR

22. Juli 2025, 10:00 UTC

Ergebnisse

Danaher 2Q EPS 77c >DHR

22. Juli 2025, 09:34 UTC

Heiße Aktien

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

14. Juli 2025, 16:12 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

22. Apr. 2025, 10:02 UTC

Ergebnisse

Danaher Still Sees 2025 Adjusted Core Revenue Up About 3% >DHR

22. Apr. 2025, 10:02 UTC

Ergebnisse

Danaher Sees 2025 Adj EPS $7.60-Adj EPS $7.75 >DHR

22. Apr. 2025, 10:02 UTC

Ergebnisse

Danaher Sees 2Q Adjusted Core Revenue Up Low-Single Digits >DHR

22. Apr. 2025, 10:01 UTC

Ergebnisse

Danaher: Macro Backdrop Has Become More Dynamic Since Start of Year >DHR

22. Apr. 2025, 10:01 UTC

Ergebnisse

Danaher 1Q Adjusted Core Revenue Flat >DHR

22. Apr. 2025, 10:00 UTC

Ergebnisse

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

Peer-Vergleich

Kursveränderung

Danaher Corp Prognose

Kursziel

By TipRanks

9.17% Vorteil

12-Monats-Prognose

Durchschnitt 243.45 USD  9.17%

Hoch 260 USD

Tief 220 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Danaher Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

14 ratings

11

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

189.8851 / 196.5Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

111 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat